Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer

NCT00415818 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT00415818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00415818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer
Lead sponsor
Transgene
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2005
Completion date
March 31, 2010
Enrollment
148 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung